Fig. 1: COX6B2 is increased in PDAC and associated with poor prognosis.
a The bar plot shows the log2 (fold changes) of nuclear encoded OXPHOS genes between PDAC and normal tissues from TCGA and GTEx datasets, respectively. Red and blue bars indicate increase and decrease in gene expression, respectively. b Immunohistochemistry results of COX6B2 in PDAC tissues (n = 27) and matched adjacent normal tissues (n = 27). Representative immunohistochemistry photomicrographs (upper panel) at 100× (scale bar = 100 μm) and 400× (scale bar = 25 μm) magnification, quantitative results (lower left panel), and expression changes in PDAC tissues (lower right panel), respectively. c Western blot analysis of COX6B2 in fresh PDAC (T) and paired adjacent normal tissues (N). d Western blot analysis of COX6B2 in the HPNE (hTERT-HPNE) normal pancreatic ductal epithelial cell line and 5 PDAC cell lines. e Tumor samples are grouped by histological grade: G0 (n = 4), G1 (n = 31), G2 (n = 96), and G3 (n = 49). The column shows a dot map of the expression of COX6B2 in PDAC with different histological grades: G0 + G1 compared with G2 + G3. f Comparison of COX6B2 mRNA levels in PDAC tissues with (Stage II + III + IV, n = 140) or without (Stage I, n = 29) distance metastasis. g, h Overall (g) and disease-free (h) survival between patients with high (red) and low (blue) levels of COX6B2 mRNA from the TCGA database (http://gepia.cancer-pku.cn). Patients with high and low levels of COX6B2 were grouped with cut-off using quartile value. All data are presented as mean ± SEM (n ≥ 3). *P < 0.05, ***P < 0.001.
